Identification

Name
Ethanol
Accession Number
DB00898  (APRD00738)
Type
Small Molecule
Groups
Approved
Description

A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.

Structure
Thumb
Synonyms
  • 1-Hydroxyethane
  • Alcohol
  • Alcohol (ethyl)
  • Alcohol anhydrous
  • Alcohol denatured
  • Alcohol etílico
  • Alcohol, denatured
  • Alcool éthylique
  • Alkohol
  • Äthanol
  • Äthylalkohol
  • Dehydrated ethanol
  • etanol
  • éthanol
  • Ethyl Alcohol
  • Grain alcohol
  • Hydroxyethane
  • Methylcarbinol
  • Spiritus vini
External IDs
B3324 / Caswell No. 426 / Fema no. 2419 / NCI-C03134 / NSC-85228 / PM-6193-200 / USAF EK-1597
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dehydrated Alcohol InjectionLiquid0.995 mlIntramuscular; SubcutaneousHospira, Inc.1948-12-312012-08-03Canada
Dehydrated Alcohol Injection USPLiquid100 %IntravenousSandoz Canada Incorporated1978-12-31Not applicableCanada
Germ FighterLotion62 %TopicalXttrium Laboratories, Inc.Not applicableNot applicableCanada
Healing Waters Aloe Cucumber Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters Cotton Blossom Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters Lemon Verbena Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters Peach Nectarine Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters Sweet Pea Lily Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters Violet Rose Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Healing Waters White Tea Pear Hand SanitizerLiquid60 g/100gTopicalNingbo Meiduo General Products Co., Ltd2010-02-20Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
1.8oz Hand Sanitizer With Clip -assortedGel62 mL/1TopicalNingbo Liyuan Daily Chemical Products Co., Ltd.2017-01-01Not applicableUs
2 Pack Assured Instant Hand Sanitizer with moisturizers (Vitamin E and aloe)Gel62 mL/100mLTopicalGreenbrier International, Inc.2013-06-22Not applicableUs
2 Pack Assured Instant Hand Sanitizer with moisturizers (Vitamin E and aloe) lemon scentedGel62 mL/100mLTopicalNingbo Pulisi Daily Chemical Products2014-05-10Not applicableUs
2-Pack Hand SanitizerGel36.7 mL/59.2mLTopicalGreenbrier International, Inc.2013-05-24Not applicableUs
2pk 2oz Hand Sanitiizer-aloe VeraLiquid62 mL/1TopicalNingbo Liyuan Daily Chemical Products Co., Ltd.2017-04-01Not applicableUs
3 Hand SanitizersKitTopicalGreenbrier International, Inc.2012-06-13Not applicableUs
3 Hand SanitizersKitTopicalNingbo Pulisi Daily Chemical Products2014-01-03Not applicableUs
3 Hand SanitizersKitTopicalInternational Wholesale, Inc.2014-11-15Not applicableUs
3 Hand Sanitizers KitKitTopicalGreenbrier International, Inc.2012-08-15Not applicableUs
3 Pack Assured Instant Hand Sanitizer with moisturizers (aloe vera and moisturizers)Gel62 mL/100mLTopicalNingbo Pulisi Daily Chemical Products2014-11-02Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
1.8oz Armstrong Hand Sanitizer with Aloe Vera and Vitamin EGel65 mL/100mLTopicalBlue Cross Laboratories2017-10-25Not applicableUs
AlcoholLiquid63 mg/mLTopicalS.P. Richards Company2017-11-03Not applicableUs
Alcohol swabSwab.7 mL/mLTopicalPharmaplast SAE2007-01-012016-10-25Us
Assured AloeGel70 mL/100mLTopicalGreenbrier International, Inc.2017-11-28Not applicableUs
Assured AloeGel70 mL/100mLTopical4 E Global, S.A.P.I. De C.V2017-10-27Not applicableUs
BlancTis Essence tooth whitening gelGel, dentifrice500 mg/gDentalNibec Co., Ltd2010-03-052017-06-29Us
BlancTis Forte II tooth whiteningGel, dentifrice500 mg/gDentalNibec Co., Ltd2010-07-242017-06-29Us
BOARDWALK Hand SanitizerGel.7 mL/mLTopicalEssendant Co.2015-08-30Not applicableUs
DDM Decolorized IodineLiquid.45 mL/mLTopicalDiscount Drug Mart1998-03-25Not applicableUs
De La Cruz Decolorized IodineLiquid.45 mL/mLTopicalDLC Laboratories, Inc.1998-03-25Not applicableUs
International/Other Brands
Dehydrated ethanol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIEthanol + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ibuprofen + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSIEthanol + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ibuprofen + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
3M AvagardEthanol (506.3 mg/mL) + Chlorhexidine gluconate (8.3 mg/mL)LotionTopical3 M Pharmaceuticals2001-06-14Not applicableUs
50 Person ANSIEthanol + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ibuprofen + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
ACME FIRST AID Contains 404 PIECESEthanol + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitAcme United Corporation2010-04-27Not applicableUs
ActiprepEthanol (83 %) + Pyrithione zinc (1 %)LiquidTopicalHealthpoint2002-09-122004-07-13Canada
Adventure First Aid .5 TinEthanol + Benzalkonium chloride + BenzocaineKitOral; TopicalTender Corporation2015-10-01Not applicableUs
Adventure First Aid Water ResistantEthanol + BenzocaineKitOral; TopicalTender Corporation2015-10-01Not applicableUs
After Bite WipeEthanol (.5 mL/mL) + Lidocaine hydrochloride (20 mg/mL)LiquidTopicalTender Corporation2016-11-012016-11-08Us
After Bite WipeEthanol (.5 mL/mL) + Lidocaine hydrochloride (20 mg/mL)LiquidTopicalTender Corporation2016-11-01Not applicableUs
Categories
UNII
3K9958V90M
CAS number
64-17-5
Weight
Average: 46.0684
Monoisotopic: 46.041864814
Chemical Formula
C2H6O
InChI Key
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
InChI
InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
IUPAC Name
ethanol
SMILES
CCO

Pharmacology

Indication

For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.

Structured Indications
Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
AGlycine receptor subunit alpha-1
agonist
Human
AGlycine receptor subunit alpha-2
agonist
Human
UVoltage-dependent L-type calcium channel subunit beta-1Not AvailableHuman
U5-hydroxytryptamine receptor 3ANot AvailableHuman
UGamma-aminobutyric acid receptor subunit alpha-2Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-10Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
UGamma-aminobutyric acid receptor subunit alpha-5Not AvailableHuman
UGamma-aminobutyric acid receptor subunit alpha-4Not AvailableHuman
UGamma-aminobutyric acid receptor subunit alpha-3Not AvailableHuman
UGlutamate receptor 1Not AvailableHuman
UVoltage-dependent calcium channel gamma-1 subunitNot AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-2Not AvailableHuman
UGamma-aminobutyric acid receptor subunit alpha-6Not AvailableHuman
UGlutamate receptor 2Not AvailableHuman
UGlutamate receptor 4Not AvailableHuman
UGlutamate receptor 3Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHuman
UG protein-activated inward rectifier potassium channel 1Not AvailableHuman
UG protein-activated inward rectifier potassium channel 2Not AvailableHuman
UVascular cell adhesion protein 1Not AvailableHuman
UEquilibrative nucleoside transporter 1Not AvailableHuman
UG protein-activated inward rectifier potassium channel 4Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-7Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-9Not AvailableHuman
UGamma-aminobutyric acid receptor subunit beta-1Not AvailableHuman
UGamma-aminobutyric acid receptor subunit beta-3Not AvailableHuman
UGamma-aminobutyric acid receptor subunit beta-2Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1SNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1DNot AvailableHuman
UNeuronal acetylcholine receptor subunit beta-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-3Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-5Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-6Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-3Not AvailableHuman
UGamma-aminobutyric acid receptor subunit gamma-1Not AvailableHuman
UGamma-aminobutyric acid receptor subunit gamma-3Not AvailableHuman
UGamma-aminobutyric acid receptor subunit epsilonNot AvailableHuman
UGamma-aminobutyric acid receptor subunit piNot AvailableHuman
UGamma-aminobutyric acid receptor subunit thetaNot AvailableHuman
UGamma-aminobutyric acid receptor subunit deltaNot AvailableHuman
UEquilibrative nucleoside transporter 2Not AvailableHuman
U5-hydroxytryptamine receptor 3ENot AvailableHuman
U5-hydroxytryptamine receptor 3BNot AvailableHuman
U5-hydroxytryptamine receptor 3DNot AvailableHuman
U5-hydroxytryptamine receptor 3CNot AvailableHuman
UVoltage-dependent calcium channel gamma-2 subunitNot AvailableHuman
UG protein-activated inward rectifier potassium channel 3Not AvailableHuman
UNeural cell adhesion molecule L1Not AvailableHuman
Absorption

Rapidly absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat LD50: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Disulfiram Action PathwayDrug action
Ethanol DegradationMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Ethanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Ethanol can be increased when it is combined with Abiraterone.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Ethanol.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
AcetaminophenEthanol may increase the hepatotoxic activities of Acetaminophen.Approved
AcetohexamideThe risk or severity of adverse effects can be increased when Acetohexamide is combined with Ethanol.Investigational, Withdrawn
Acetohydroxamic AcidThe risk or severity of adverse effects can be increased when Ethanol is combined with Acetohydroxamic Acid.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ethanol is combined with Acetylsalicylic acid.Approved, Vet Approved
AcitretinEthanol may increase the teratogenic activities of Acitretin.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethanol is combined with Alaproclate.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
AmantadineEthanol may increase the central nervous system depressant (CNS depressant) activities of Amantadine.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Ethanol.Approved
AmiodaroneThe metabolism of Ethanol can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Ethanol is combined with Amphetamine.Approved, Illicit
AprepitantThe serum concentration of Ethanol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Ethanol.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
AtazanavirThe metabolism of Ethanol can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ethanol can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ethanol is combined with Atorvastatin.Approved
AvanafilEthanol may increase the hypotensive activities of Avanafil.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational, Vet Approved
AzelastineEthanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Ethanol can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit
BedaquilineEthanol may increase the hepatotoxic activities of Bedaquiline.Approved
BendroflumethiazideEthanol may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Ethanol is combined with Benmoxin.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
BoceprevirThe metabolism of Ethanol can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ethanol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ethanol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ethanol.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Ethanol is combined with Brofaromine.Experimental
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromocriptine.Approved, Investigational
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Withdrawn
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
BuprenorphineEthanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Ethanol is combined with Bupropion.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ethanol.Approved
CaffeineThe metabolism of Ethanol can be decreased when combined with Caffeine.Approved
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CarbutamideThe risk or severity of adverse effects can be increased when Carbutamide is combined with Ethanol.Experimental
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit, Investigational, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Caroxazone.Withdrawn
CefotetanThe risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol.Approved
CeritinibThe serum concentration of Ethanol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ethanol.Withdrawn
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Vet Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ethanol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ChlorothiazideEthanol may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
ChlorpropamideThe risk or severity of adverse effects can be increased when Chlorpropamide is combined with Ethanol.Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Withdrawn
ChlorthalidoneEthanol may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ethanol.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
CisaprideThe risk or severity of adverse effects can be increased when Cisapride is combined with Ethanol.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Ethanol is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ethanol can be decreased when combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ClobazamEthanol may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be decreased when it is combined with Ethanol.Experimental
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
ClotrimazoleThe metabolism of Ethanol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CobicistatThe metabolism of Ethanol can be decreased when combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
ConivaptanThe serum concentration of Ethanol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ethanol can be decreased when combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
CyclopenthiazideEthanol may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CycloserineEthanol may increase the neurotoxic activities of Cycloserine.Approved
CyclosporineThe metabolism of Ethanol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Cyproterone acetateThe therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ethanol.Approved, Investigational
CysteamineThe risk or severity of adverse effects can be increased when Ethanol is combined with Cysteamine.Approved, Investigational
DabrafenibThe serum concentration of Ethanol can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethanol is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ethanol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethanol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ethanol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethanol can be decreased when combined with Delavirdine.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethanol is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Ethanol.Approved
DidanosineThe risk or severity of adverse effects can be increased when Ethanol is combined with Didanosine.Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Ethanol is combined with Diethylpropion.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ethanol.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ethanol.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ethanol.Experimental
DihydroergotamineThe metabolism of Ethanol can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
DiltiazemThe metabolism of Ethanol can be decreased when combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DiphenadioneThe serum concentration of Diphenadione can be decreased when it is combined with Ethanol.Experimental
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Ethanol.Approved
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
DosulepinThe metabolism of Ethanol can be decreased when combined with Dosulepin.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
DoxycyclineThe metabolism of Ethanol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineEthanol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
DronedaroneThe metabolism of Ethanol can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethanol is combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethanol.Approved, Investigational
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
EluxadolineThe risk or severity of adverse effects can be increased when Ethanol is combined with Eluxadoline.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
EnzalutamideThe serum concentration of Ethanol can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ethanol.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ethanol.Approved
Erythrityl TetranitrateEthanol may increase the vasodilatory activities of Erythrityl Tetranitrate.Approved, Investigational
ErythromycinThe metabolism of Ethanol can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Withdrawn
EthionamideThe risk or severity of adverse effects can be increased when Ethanol is combined with Ethionamide.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Ethanol.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational, Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Etoperidone.Withdrawn
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethanol is combined with Ezogabine.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational, Vet Approved
FesoterodineEthanol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
FlibanserinEthanol may increase the hypotensive activities of Flibanserin.Approved
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
FluconazoleThe metabolism of Ethanol can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
FluindioneThe serum concentration of Fluindione can be decreased when it is combined with Ethanol.Investigational
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ethanol.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ethanol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethanol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinEthanol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Ethanol can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
Gabapentin EnacarbilEthanol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
GlibornurideThe risk or severity of adverse effects can be increased when Glibornuride is combined with Ethanol.Investigational, Withdrawn
GliclazideThe risk or severity of adverse effects can be increased when Gliclazide is combined with Ethanol.Approved
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with Ethanol.Approved
GlipizideThe risk or severity of adverse effects can be increased when Glipizide is combined with Ethanol.Approved
GliquidoneThe risk or severity of adverse effects can be increased when Gliquidone is combined with Ethanol.Approved, Investigational
GlisoxepideThe risk or severity of adverse effects can be increased when Glisoxepide is combined with Ethanol.Approved, Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
GlyburideThe risk or severity of adverse effects can be increased when Glyburide is combined with Ethanol.Approved
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Ethanol.Approved, Vet Approved
GuanfacineEthanol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Ethanol is combined with Harmaline.Experimental
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Hydracarbazine.Experimental
HydrochlorothiazideEthanol may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneEthanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideEthanol may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ImatinibThe metabolism of Ethanol can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethanol is combined with Indalpine.Investigational, Withdrawn
IndapamideEthanol may increase the orthostatic hypotensive activities of Indapamide.Approved
IndinavirThe metabolism of Ethanol can be decreased when combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
IproclozideThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Ethanol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Ethanol is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
IsoniazidThe metabolism of Ethanol can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateEthanol may increase the vasodilatory activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateEthanol may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
IsotretinoinThe risk or severity of adverse effects can be increased when Ethanol is combined with Isotretinoin.Approved
IsradipineThe metabolism of Ethanol can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ethanol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethanol can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Ethanol.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
LevomilnacipranEthanol can cause an increase in the absorption of Levomilnacipran resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Ethanol.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LobeglitazoneThe metabolism of Ethanol can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit
LomitapideEthanol may increase the hepatotoxic activities of Lomitapide.Approved
LopinavirThe metabolism of Ethanol can be decreased when combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LovastatinThe metabolism of Ethanol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
LuliconazoleThe serum concentration of Ethanol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ethanol can be increased when combined with Lumacaftor.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ethanol.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MebanazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Mebanazine.Withdrawn
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
MetahexamideThe risk or severity of adverse effects can be increased when Metahexamide is combined with Ethanol.Experimental
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ethanol.Experimental
MetforminThe risk or severity of adverse effects can be increased when Ethanol is combined with Metformin.Approved
MethadoneEthanol may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MethotrimeprazineEthanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MethyclothiazideEthanol may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ethanol.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Methylpropylpropanediol dinitrateEthanol may increase the vasodilatory activities of Methylpropylpropanediol dinitrate.Experimental
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ethanol.Approved
MetolazoneEthanol may increase the orthostatic hypotensive activities of Metolazone.Approved
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Ethanol.Approved
MetyrosineEthanol may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ethanol.Experimental
MexiletineThe metabolism of Ethanol can be decreased when combined with Mexiletine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
MidostaurinThe metabolism of Ethanol can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Ethanol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ethanol is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Ethanol is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
MipomersenEthanol may increase the hepatotoxic activities of Mipomersen.Approved
MirodenafilEthanol may increase the hypotensive activities of Mirodenafil.Investigational
MirtazapineEthanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ethanol can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Ethanol is combined with Moclobemide.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ethanol can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ethanol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ethanol can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of adverse effects can be increased when Ethanol is combined with Niacin.Approved, Investigational, Nutraceutical
NialamideThe risk or severity of adverse effects can be increased when Ethanol is combined with Nialamide.Withdrawn
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ethanol.Approved, Investigational
NicotineThe metabolism of Ethanol can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ethanol.Approved
NilotinibThe metabolism of Ethanol can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
NitroglycerinEthanol may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Ethanol is combined with Octamoxin.Withdrawn
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
OlaparibThe metabolism of Ethanol can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
OrphenadrineEthanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
OsimertinibThe serum concentration of Ethanol can be increased when it is combined with Osimertinib.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OxcarbazepineEthanol may increase the central nervous system depressant (CNS depressant) activities of Oxcarbazepine.Approved
OxethazaineOxethazaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
OxybutyninEthanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ethanol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ParaldehydeEthanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Ethanol is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
Pentaerythritol TetranitrateEthanol may increase the vasodilatory activities of Pentaerythritol Tetranitrate.Approved
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Ethanol.Approved, Investigational, Vet Approved, Withdrawn
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
PhendimetrazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenelzine.Approved
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Ethanol.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Pheniprazine.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenoxypropazine.Withdrawn
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Ethanol.Approved, Investigational
PhentermineThe risk or severity of adverse effects can be increased when Ethanol is combined with Phentermine.Approved, Illicit
PhenytoinEthanol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Ethanol is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ethanol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Pivhydrazine.Withdrawn
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PolythiazideEthanol may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PosaconazoleThe metabolism of Ethanol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleEthanol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ethanol.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Procarbazine.Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
PropatylnitrateEthanol may increase the vasodilatory activities of Propatylnitrate.Experimental, Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Ethanol.Approved, Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
QuinethazoneEthanol may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
RanolazineThe metabolism of Ethanol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ethanol is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
RifabutinThe metabolism of Ethanol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ethanol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethanol can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Ethanol.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
RopiniroleEthanol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ethanol.Approved
RotigotineEthanol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Ethanol is combined with Rufinamide.Approved
SafrazineThe risk or severity of adverse effects can be increased when Ethanol is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Ethanol can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Ethanol.Approved
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Ethanol is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethanol is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
SildenafilEthanol may increase the hypotensive activities of Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ethanol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ethanol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ethanol.Approved
Sodium oxybateEthanol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Ethanol can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolStiripentol may increase the sedative activities of Ethanol.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
SulfisoxazoleThe metabolism of Ethanol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
SuvorexantEthanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusEthanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
TadalafilEthanol may increase the hypotensive activities of Tadalafil.Approved, Investigational
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
TapentadolEthanol may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TelaprevirThe metabolism of Ethanol can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ethanol can be decreased when combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TenitramineEthanol may increase the vasodilatory activities of Tenitramine.Experimental
Tenofovir disoproxilThe metabolism of Ethanol can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ethanol.Experimental
TeriflunomideThe serum concentration of Ethanol can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Investigational
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Ethanol.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
TiclopidineThe metabolism of Ethanol can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
TinidazoleThe risk or severity of adverse effects can be increased when Tinidazole is combined with Ethanol.Approved, Investigational
TioclomarolThe serum concentration of Tioclomarol can be decreased when it is combined with Ethanol.Experimental
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TocilizumabThe serum concentration of Ethanol can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe risk or severity of adverse effects can be increased when Tolazamide is combined with Ethanol.Approved
TolbutamideThe risk or severity of adverse effects can be increased when Tolbutamide is combined with Ethanol.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Toloxatone.Approved
TopiramateEthanol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TrabectedinEthanol may increase the hepatotoxic activities of Trabectedin.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Ethanol is combined with Trazodone.Approved, Investigational
TreprostinilEthanol can cause an increase in the absorption of Treprostinil resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
TrichlormethiazideEthanol may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Vet Approved
TrimethobenzamideEthanol may increase the central nervous system depressant (CNS depressant) activities of Trimethobenzamide.Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
TrolnitrateEthanol may increase the vasodilatory activities of Trolnitrate.Experimental
TrospiumEthanol may increase the central nervous system depressant (CNS depressant) activities of Trospium.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ethanol.Approved, Investigational, Nutraceutical
UdenafilEthanol may increase the hypotensive activities of Udenafil.Approved, Investigational
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
VardenafilEthanol may increase the hypotensive activities of Vardenafil.Approved
VareniclineThe risk or severity of adverse effects can be increased when Varenicline is combined with Ethanol.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethanol is combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
VerapamilThe serum concentration of Ethanol can be increased when it is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
VoriconazoleThe metabolism of Ethanol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Ethanol.Approved
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Experimental
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethanol is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Vet Approved
ZolpidemEthanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Ethanol is combined with Zopiclone.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
ZucapsaicinThe metabolism of Ethanol can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

William S. Hedrick, "Process for ethanol production from cellulosic materials." U.S. Patent US4650689, issued June, 1917.

US4650689
General References
  1. Snyder R, Kalf GF: A perspective on benzene leukemogenesis. Crit Rev Toxicol. 1994;24(3):177-209. [PubMed:7945890]
  2. Chastain G: Alcohol, neurotransmitter systems, and behavior. J Gen Psychol. 2006 Oct;133(4):329-35. [PubMed:17128954]
  3. McDonnell G, Russell AD: Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999 Jan;12(1):147-79. [PubMed:9880479]
  4. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA: American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-46. [PubMed:12216995]
  5. Hingson R, Winter M: Epidemiology and consequences of drinking and driving. Alcohol Res Health. 2003;27(1):63-78. [PubMed:15301401]
External Links
Human Metabolome Database
HMDB00108
KEGG Drug
D00068
KEGG Compound
C00469
PubChem Compound
702
PubChem Substance
46506969
ChemSpider
682
ChEBI
16236
ChEMBL
CHEMBL545
Therapeutic Targets Database
DAP000681
PharmGKB
PA448073
IUPHAR
2299
Guide to Pharmacology
GtP Drug Page
HET
EOH
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethanol
ATC Codes
V03AB16 — EthanolD08AX08 — EthanolV03AZ01 — Ethanol
AHFS Codes
  • 84:04.92 — Miscellaneous Local Anti-infectives
  • 92:00.00 — Miscellaneous Therapeutic Agents
PDB Entries
1a7s / 1ab1 / 1adb / 1adc / 1alz / 1cbn / 1cll / 1cnr / 1dba / 1drb
show 207 more
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceCancer, Breast1
0CompletedNot AvailableAlcohol Consumption / Tobacco Use1
0CompletedBasic ScienceHealthy Volunteers1
0RecruitingBasic ScienceAlcohol Use Disorder (AUD)1
0RecruitingOtherPsychomotor Impairment1
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
0RecruitingTreatmentChemotherapy Symptoms1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingTreatmentAnxiety Preoperative / Feeling Anxious1
1Active Not RecruitingTreatmentGamma Delta Hepatosplenic T-Cell Lymphoma / NK T-Cell Lymphoma / Subcutaneous Panniculitis-Like T-Cell Lymphoma / T-Cell Peripheral Lymphoma1
1CompletedNot AvailableAlcohol-Related Disorders / Amphetamine-Related Disorders1
1CompletedNot AvailableChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableComplication of Urinary Catheter1
1CompletedNot AvailableObese1
1CompletedBasic ScienceAlcohol or Other Drugs Effects1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceHeavy Drinking1
1CompletedBasic SciencePharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol1
1CompletedSupportive CareNeuroblastomas1
1CompletedTreatmentCentral Nervous System1
1CompletedTreatmentNeoplasms, Cystic, Mucinous, and Serous1
1Not Yet RecruitingBasic ScienceAlcohol Drinking1
1Not Yet RecruitingOtherIntracranial Pathology1
1RecruitingBasic ScienceAlcohol Abuse1
1RecruitingBasic ScienceAlcohol Drinking / Men / Sex Behavior1
1RecruitingTreatmentThyroid Nodules1
1TerminatedTreatmentAlcoholism / Genetics1
1TerminatedTreatmentBenign Neoplasm of Pancreas / Mucinous Cystadenocarcinoma of Pancreas / Mucinous Cystadenoma of Pancreas / Mucinous Cystic Tumor With Moderate Dysplasia1
1TerminatedTreatmentType 2 Diabetes Mellitus1
1Unknown StatusTreatmentPancreatic Mucinous-Cystic Neoplasm1
1, 2Active Not RecruitingPreventionBloodstream Infection Due to Hickman Catheter / Catheter-related Bloodstream Infection (CRBSI) Nos / Catheter-related Bloodstream Infection Due to Central Venous Catheter1
1, 2CompletedTreatmentAlcohol Use Disorder (AUD)1
1, 2CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Benign Prostatic Hypertrophy (BPH) / Prostate Disease1
1, 2WithdrawnSupportive CareChronic Myeloproliferative Disorders / Infection NOS / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unspecified Adult Solid Tumor, Protocol Specific1
2Active Not RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-Cell Lymphomas1
2Active Not RecruitingTreatmentLymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentRecurrent Herpes Labialis1
2CompletedNot AvailableCongenital Venous Malformation1
2CompletedOtherAlcohol Drinking / Alcoholism / FMRI1
2CompletedPreventionNeurobehavioral Manifestations / Sleep1
2CompletedTreatmentInfection NOS1
2CompletedTreatmentLymphoma, AIDS Related1
2CompletedTreatmentMucinous Pancreatic Cysts1
2CompletedTreatmentOccasional Constipation1
2CompletedTreatmentRecurrent Herpes Labialis1
2CompletedTreatmentTremors1
2Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2RecruitingOtherActive Ethanol and Active Iomazenil / Active Ethanol and Placebo Iomazenil / Placebo Ethanol and Active Iomazenil / Placebo Ethanol and Placebo Iomazenil1
2RecruitingPreventionCessation, Smoking1
2RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Burkitt's Lymphoma / Gray Zone Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Primary mediastinal large B-cell lymphomas / Primary Meidastinal Lymphoma1
2RecruitingTreatmentLymphoma, AIDS Related / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentLymphomatoid Granulomatosis / Lymphoproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentEnd Stage Renal Failure, Hemodialysis1
2Unknown StatusPreventionAlcoholic Intoxication / Neurobehavioral Manifestations1
2Unknown StatusPreventionType 2 Diabetes Mellitus1
2Unknown StatusTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2WithdrawnPreventionCatheter Related Infections / Short Bowel Syndrome (SBS)1
2, 3Active Not RecruitingBasic ScienceSpasmodic Dysphonia / Vocal Fold Nodules / Voice Tremor1
2, 3Not Yet RecruitingTreatmentPrecancerous Type Pancreatic Cyst1
2, 3RecruitingTreatmentNonvalvular Atrial Fibrillation / Ventricular Tachycardia (VT)1
3Active Not RecruitingDiagnosticAlcohol Impaired Driving / Driving / Impairment / Intoxication1
3CompletedPreventionCentral Line-Associated Bloodstream Infection1
3CompletedTreatmentDental Plaque1
3CompletedTreatmentNeutropenias1
3Enrolling by InvitationTreatmentAromatherapy / Drug withdrawal syndrome neonatal1
3Not Yet RecruitingPreventionTunnelled Hemodialysis Catheter Infection1
3RecruitingPreventionCentral Line-associated Bloodstream Infection (CLABSI) / Ethanol-lock / Infection, Catheter-Related / Pediatric1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentSkin-structure infections1
3TerminatedTreatmentBloodstream Infections1
3WithdrawnTreatmentUrinary Tract Infections (UTIs)1
4CompletedBasic ScienceSleeplessness1
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentEndometriosis / Pelvic Pain1
4CompletedTreatmentHand Hygiene Effectiveness1
4CompletedTreatmentMalignant Neoplasm of Pancreas1
4CompletedTreatmentSevere alcoholic liver disease1
4Not Yet RecruitingTreatmentAlcohol Consumption / Smoking, Cigarette1
4Unknown StatusTreatmentAmputation Wound / Wound Infections1
4Unknown StatusTreatmentIngrown Toenail1
Not AvailableActive Not RecruitingScreeningAlcoholism1
Not AvailableActive Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedNot AvailableAlcohol Abuse / Alcohol Related Disorders / Alcoholism1
Not AvailableCompletedNot AvailableAlcoholism2
Not AvailableCompletedNot AvailableDrug Dependence1
Not AvailableCompletedNot AvailableMalignant Neoplasm of Pancreas / Pancreatitis, Chronic1
Not AvailableCompletedBasic ScienceAlcohol Drinking / Cannabis1
Not AvailableCompletedBasic ScienceAlcoholism1
Not AvailableCompletedBasic ScienceFocus: Effects of Nicotine and Alcohol on Brain Circuits1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic SciencePsychomotor Impairment1
Not AvailableCompletedOtherAutomobile Driving1
Not AvailableCompletedPreventionCatheter-Related Infections1
Not AvailableCompletedTreatmentAlcohol Drinking / Attention Deficit Disorder (ADD) / Cessation, Smoking / Depression1
Not AvailableCompletedTreatmentAnaesthesia therapy / Pain1
Not AvailableCompletedTreatmentStings1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableEnrolling by InvitationBasic ScienceBrain Function / Cerebral Blood Flow / Gut Microbiome / Metabolism1
Not AvailableEnrolling by InvitationTreatmentEndometriosis / Endometriotic Cysts1
Not AvailableRecruitingBasic ScienceAlcohols / Nonvalvular Atrial Fibrillation1
Not AvailableRecruitingSupportive CareAbdominal Cancer1
Not AvailableRecruitingTreatmentAlcoholic Intoxication1
Not AvailableRecruitingTreatmentPeriodontitis / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentThyroid Papillary Carcinoma1
Not AvailableTerminatedPreventionBacteremia / Infection Associated With Catheter / Sepsis1
Not AvailableTerminatedPreventionCatheter Related Infections1
Not AvailableWithdrawnNot AvailableAutomobile Driving1

Pharmacoeconomics

Manufacturers
  • Miles laboratories inc
Packagers
Dosage forms
FormRouteStrength
GelTopical62 mL/1
GelTopical36.7 mL/59.2mL
LiquidTopical62 mL/1
KitTopical
LiquidTopical496 mg/mL
LiquidTopical548 mg/mL
GelTopical577.7 mg/mL
GelTopical70 mL/1
GelTopical21.024 mL/30mL
GelTopical266.304 mL/380mL
LotionTopical.79 mL/mL
Aerosol, sprayTopical62 mL/mL
GelTopical616 mg/mL
GelTopical70 kg/100L
GelTopical616 mg/100mL
GelTopical616 mL/mL
GelTopical70 mL/100mL
GelTopical700 mg/mL
GelTopical62 g/53mL
KitOral; Topical
LiquidTopical60 mL/100mL
SolutionTopical80 mL/100mL
LiquidTopical62 mg/mL
SwabTopical1.31 g/1
SolutionIntravenous
SwabTopical700 mg/g
SwabTopical70 mL/1
SwabTopical70 mL/100mL
SwabTopical.7 mL/mL
ClothTopical.31 mL/mL
LiquidTopical
LiquidTopical1 mL/mL
LiquidTopical720 g/L
LiquidTopical700 mL/1000mL
SprayTopical710 g/1000mL
LiquidRespiratory (inhalation)
LiquidTopical800 mg/mL
SoapTopical600 mL/L
GelTopical377.5 mL/500mL
GelTopical630 mg/mL
GelTopical18.335 mL/29.574mL
GelTopical60 mL/100mL
SprayTopical72 mL/100mL
Kit
GelTopical620 g/kg
LiquidTopical620 g/L
GelTopical65 mg/100mL
GelTopical77 mL/100mL
SolutionTopical.62 mL/mL
SprayTopical620 mg/mL
SprayTopical4.96 mL/8mL
SwabTopical.62 mL/1
LiquidTopical1.313 mg/mL
LiquidOral62 mL/100mL
LiquidTopical665 mg/L
LiquidTopical700 mL/L
PatchTopical65.9 g/100g
LiquidTopical65.9 g/100g
GelTopical19.66 mL/29.57mL
GelTopical39.33 mL/59.14mL
SprayTopical2.79 mL/4.5mL
SprayTopical5.58 mL/9mL
LotionTopical62 mL/100mL
ClothTopical.6 g/1
ClothTopical665 mL/L
LiquidTopical665 mL/L
CreamTopical620 mg/g
LiquidTopical75 g/100g
SprayTopical600 mL/L
GelTopical69 %
LotionTopical530.7 mg/mL
JellyTopical
StickTopical
GelTopical60.14 %
ClothTopical60.14 %
GelTopical.7 L/L
GelTopical42 mg/25mL
LiquidTopical.29326 L/.473L
SolutionTopical600 mg/mL
ClothTopical65.9 mL/100mL
Gel, dentifriceDental500 mg/g
LotionTopical62 dL/100dL
CreamTopical70 mL/100mL
GelTopical.65 mg/100mL
LiquidTopical82 mL/100mL
GelTopical.26 g/26g
LiquidTopical26.36 g/44mL
Aerosol, foamTopical.625 mg/mg
LipstickTopical65 mL/100mL
LiquidTopical710 g/L
SyrupOral
ClothTopical70 %
LiquidTopical70 %
GelTopical37 mL/60mL
LiquidTopical65.2 mL/100mL
GelTopical39.184 g/70mL
GelTopical36.58 g/59mL
ClothTopical3.32 g/1
LiquidTopical63 mg/mL
SolutionTopical67 mL/100mL
SolutionTopical71 mL/100mL
SprayTopical.62 g/g
LiquidTopical338.82 g/L
MouthwashDental
LiquidTopical585 g/mL
LiquidTopical.48 mL/mL
GelTopical58.1 mg/g
SprayTopical56 mg/g
LiquidTopical72 mL/100mL
LiquidTopical70 L/100L
LiquidTopical.8 mL/mL
LiquidTopical.45 mL/mL
InjectionIntraspinal.98 mL/mL
Injection, solutionIntraspinal.98 mL/mL
SolutionIntraspinal.98 mL/mL
LiquidIntramuscular; Subcutaneous0.995 ml
LiquidIntravenous100 %
Aerosol, foamTopical65 mL/100mL
GelTopical
SprayTopical
LiquidTopical81.11 mL/100mL
LiquidTopical66 %
Aerosol, foamTopical62.5 g/100g
SolutionTopical70 mL/100mL
Aerosol, foamTopical62 g/100g
LiquidTopical38.7 g
LiquidOral
GelTopical7 mL/10mL
GelTopical800 mg/1.2mL
SprayTopical800 mg/1.2mL
SolutionTopical540.02 mg/mL
SolutionTopical589.4 mg/mL
SolutionTopical598.5 mg/mL
GelTopical620 mg/g
SolutionTopical7 mL/10mL
ClothTopical.7 1/1
SprayTopical7 mL/10mL
LiquidTopical22.5 mL/30mL
LiquidTopical.67 mL/100mL
LiquidTopical.7 mL/100mL
GelTopical.5634 g/mL
Aerosol, foamTopical62 mL/100mL
ClothTopical65 mL/1
GelTopical61.9937 mL/100mL
GelTopical.62 mL/mL
GelTopical.7 g/g
SolutionTopical.67 mL/mL
LiquidCutaneous70 mL/100mL
LiquidTopical610 mg/mL
ClothTopical62 mL/100mL
GelTopical600 mL/1000mL
LiquidTopical128.21 g/1
LiquidTopical48 g/100mL
LiquidTopical70 g/100mL
LiquidTopical75 mL/100mL
SoapTopical.072 mg/mL
GelTopical36.58 mL/59mL
GelTopical66 g/100g
LiquidTopical65 mL/100mL
LotionTopical185 mL/295mL
Aerosol, foamTopical.62 g/g
SoapTopical.07 mg/mL
SoapTopical.67 mL/mL
GelTopical69.5 g/100g
LotionTopical63 %
LotionTopical62 %
SolutionTopical630 g/1000g
GelTopical620 mL/1000mL
LiquidTopical
GelTopical46.5 mL/75mL
MouthwashOral
LotionTopical70 mL/100mL
GelTopical15.67 mg/30mL
GelTopical130.65 mg/250mL
GelTopical16.41 mg/30mL
LiquidTopical35.15 g/60mL
LiquidTopical.71 L/L
GelTopical.7 mg/mL
LiquidTopical.62 mL/mL
GelPercutaneous62 mL/100mL
GelTopical.62 g/g
GelTopical.65 kg/100L
GelTopical146.3 mL/236mL
GelTopical184.6 mL/355mL
GelTopical53.5 g/100mL
GelTopical540.26 g/L
GelTopical545 mg/mL
GelTopical567 mg/mL
GelTopical578 mg/mL
GelTopical585 mg/mL
GelTopical62 mL/mL
GelTopical65 mL/100L
GelTopical650 mL/mL
GelTopical700 mL/100mL
GelTopical837 mg/mL
GelTopical9.3 mL/60mL
LiquidTopical.879 mg/mL
LiquidTopical36.58 mL/59mL
LiquidTopical53.3 g/100mL
LiquidTopical616 mg/mL
LiquidTopical62 kg/100L
LiquidTopical620 mL/1000mL
LiquidTopical630 mL/1000mL
LiquidTopical71 mL/100mL
LotionTopical.073 mL/100L
LotionTopical558 mg/mL
LotionTopical567 mg/mL
SprayTopical.63 mL/mL
SwabTopical63 mL/100mL
GelTopical5 mL/8mL
SwabTopical65 mL/100mL
GelTopical62 %
LiquidTopical62 g/100mL
LiquidTopical60 %
GelTopical62 mg/117.6mL
LiquidTopical63 mL/100mL
SprayTopical4.58 mL/7.39mL
SprayTopical62 g/100g
SprayTopical65 g/100g
GelTopical62 g/100mL
ClothTopical620 mg/g
LiquidTopical65 mL/mL
GelTopical70 g/100mL
GelTopical62 mg/mL
ClothTopical62 1/1001
ClothTopical620 mg/mL
LiquidTopical62 mL/100L
SprayTopical4.65 mL/7.5mL
GelTopical62 g/100g
LiquidTopical60 g/100g
LiquidTopical.3 mL/mL
SolutionTopical65 mL/100mL
SoapTopical.62 mL/mL
SolutionTopical42 mg/25mL
GelTopical6 g/200g
GelTopical2 g/200g
GelTopical6 mL/200mL
GelTopical5.4 mg/180mL
GelTopical1.8 mg/180mL
SolutionTopical1.8 mg/180mL
GelTopical4 mg/50mL
AerosolTopical
GelTopical600 mL/L
GelTopical.6329 mL/.9242mL
GelTopical10.35 mL/14.78mL
GelTopical315 mL/450mL
GelTopical42 mL/60mL
GelTopical69.8 mL/100mL
GelTopical21 g/30mL
LiquidTopical56.525 g/100mL
GelTopical63 mL/100mL
GelTopical.6 g/1
GelTopical.6 g/.9g
GelTopical.6 g/mL
GelTopical.7 g/mL
GelTopical6 mL/10mL
GelTopical60 g/mL
GelTopical65 kg/100L
GelTopical665 mg/L
GelTopical665 mL/L
GelTopical665 mL/g
GelTopical665 mL/1000mL
GelTopical700 mg/L
GelTopical700 mg/1000mL
GelTopical75 mL/100mL
LiquidTopical64.5 mL/100mL
SolutionTopical62 mL/100mL
GelTopical33 mL/53mL
GelTopical146 mL/236mL
LiquidTopical146 mL/236mL
GelTopical.665 g/mL
GelTopical18.6 mL/30mL
LiquidTopical65 g/100g
GelTopical62 mL/100mL
GelTopical62 mg/100mL
SprayTopical62 mL/100mL
GelTopical65 mL/100mL
ClothTopical
GelTopical.68 mL/mL
GelTopical680 mg/mL
SprayTopical70 mL/100mL
LotionTopical613.8 mg/mL
GelTopical14.88 g/30mL
LiquidTopical62 mg/100mL
SolutionTopical.7 L/L
SolutionPercutaneous42 mg/25mL
SprayTopical650 mg/mL
TinctureTopical
GelTopical17.98 mL/29mL
ClothTopical62 mg/1
LiquidTopical.5 g/10mL
GelTopical64.5 mL/100mL
GelTopical60.25 %
LotionTopical
GelTopical.8 L/L
GelTopical554 mL/554mL
GelTopical68 mL/100mL
LiquidTopical620 mg/g
LotionTopical.62 mL/mL
GelTopical153.34 mL/237mL
GelTopical558 mg/mL
GelTopical60 %
GelTopical19.428 mL/30mL
Gel, dentifriceDental50 g/100g
ClothTopical1 ug/mL
SprayTopical64 mL/100mL
SwabTopical75 mL/100mL
SolutionTopical70 mg/mL
SoapTopical.7 mL/mL
ClothTopical.7 mL/mL
StickTopical.7 mL/mL
ClothTopical.659 mL/1
ClothTopical.659 mL/mL
LiquidTopical17.57 g/30mL
SolutionTopical.7 mL/mL
Kit
GelTopical62 mL/62mL
SprayTopical340.56 mL/470mL
GelTopical70 g/100g
LiquidTopical75 g/100mL
SolutionTopical75.85 mL/100mL
GelTopical620 mg/mL
Aerosol, foamTopical40 mg/mL
LiquidTopical68 mg/mL
SwabTopical65.9 g/100g
GelTopical70 mg/100mL
LiquidTopical62 mL/100mL
LiquidTopical62 %
GelTopical.7 mL/mL
LiquidTopical.7 mL/mL
SwabTopical.62 mL/mL
Aerosol, foamTopical.625 mL/mL
ClothTopical.62 mL/mL
GelTopical70.0 %
SolutionTopical60 mL/100mL
SolutionTopical
GelTopical650 mg/mL
SprayTopical.62 mL/mL
SolutionTopical539.4 mg/mL
SolutionTopical539.71 mg/mL
SolutionTopical620 mg/mL
SolutionTopical54.7 g/100g
GelTopical62.5 mL/100mL
LiquidTopical68 mL/100mL
LiquidTopical62.0 %
LiquidTopical620 mg/mL
LiquidTopical700 mg/mL
GelTopical63 1/100g
LiquidTopical95 %
GelCutaneous.625 mL/mL
GelTopical64 g/100mL
LiquidTopical56.07 1/56.071
LiquidTopical650 mg/mL
Aerosol, foamTopical.67 g/mL
SolutionTopical.659 mL/mL
Aerosol, foamTopical620 mg/g
GelTopical620 mL/L
SwabTopical.659 mL/mL
SolutionTopical534 mg/mL
SoapTopical650 mL/L
SprayTopical650 mL/L
SprayTopical60 mL/100mL
ClothTopical.7 mL/.7mL
SolutionTopical62.5 mL/100mL
GelTopical.734 g/mL
SprayTopical65 mL/100mL
LiquidTopical60 L/100L
GelTopical62 g/59g
GelTopical1 g/100mL
LiquidTopical700 g/L
LiquidTopical74.4 mL/120mL
LiquidTopical146.94 mL/237mL
LiquidTopical652.2 g/1000mL
LiquidTopical672 g/1000mL
LiquidTopical693 g/1000mL
LiquidTopical710 g/1000mL
LiquidTopical62 L/100L
LiquidTopical76 L/100L
LiquidTopical67.6 mL/100mL
LiquidTopical67.6 L/100L
GelTopical670 mL/1000mL
LotionTopical18.6 mL/30mL
LotionTopical18 mL/30mL
SwabTopical1.82 mL/1
LiquidTopical.8 g/mL
GelTopical85 mL/100mL
LiquidTopical85 mL/100mL
LiquidTopical80 mL/100mL
SwabTopical
LiquidTopical850 mg/mL
LiquidTopical70 g/100g
GelTopical.6 mL/mL
SoapTopical62 mL/100mL
SolutionTopical.75 mL/mL
KitTopical
GelTopical147 mL/237mL
LiquidTopical62 g/100g
GelTopical62.5 g/100mL
GelTopical80.4 mL/120mL
Lotion; swabTopical
GelTopical70 %
ClothTopical28 g/1
KitIntramuscular; Topical
ElixirOral
LiquidTopical.72 mL/mL
GelTopical76 mL/100mL
LiquidTopical67 mL/100mL
LotionTopical60 %
LiquidTopical64.6 g/100mL
LotionTopical250 mL/295mL
LotionTopical.7 mL/mL
SolutionTopical.61 g/g
GelTopical62 g/29mL
SwabTopical70 g/100g
GelTopical146.32 mL/236mL
GelTopical215.14 mL/347mL
GelTopical496 mL/800mL
GelTopical618.1 mL/947mL
GelTopical74.4 mL/120mL
LotionTopical154 mL/236mL
GasTopical62 mL/100mL
GelTopical.62 kg/100L
GelTopical.65 mL/100L
LiquidTopical70 mL/100mL
GelTopical18 mL/30mL
LiquidTopical75 1/100mL
LotionTopical60.1 L/100L
GelTopical146 g/236g
LiquidTopical37 g/60g
LiquidTopical67.63 %
LiquidTopical6.2 mL/10mL
LiquidTopical6 mL/10mL
GelTopical44.9 mL/59.1mL
LiquidTopical.76 mL/mL
Aerosol, sprayTopical224 g/400g
GelTopical143 g/238g
Prices
Unit descriptionCostUnit
Ethanol 98% ampul7.8USD ml
Alcohol, dehydrated 98% amp4.68USD ml
Alcohol, denatured0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7081246No1996-08-032016-08-03Us
US5897031No1996-06-212016-06-21Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-114.1 °CPhysProp
boiling point (°C)78.2 °CPhysProp
water solubility1E+006 mg/L (at 25 °C)RIDDICK,JA ET AL. (1986)
logP-0.31HANSCH,C ET AL. (1995)
pKa15.9 (at 25 °C)RIDDICK,JA ET AL. (1986)
Predicted Properties
PropertyValueSource
Water Solubility579.0 mg/mLALOGPS
logP-0.4ALOGPS
logP-0.16ChemAxon
logS1.1ALOGPS
pKa (Strongest Acidic)16.47ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.01 m3·mol-1ChemAxon
Polarizability5.3 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9539
Caco-2 permeable+0.726
P-glycoprotein substrateNon-substrate0.8197
P-glycoprotein inhibitor INon-inhibitor0.9678
P-glycoprotein inhibitor IINon-inhibitor0.9542
Renal organic cation transporterNon-inhibitor0.9157
CYP450 2C9 substrateNon-substrate0.7857
CYP450 2D6 substrateNon-substrate0.9266
CYP450 3A4 substrateNon-substrate0.8073
CYP450 1A2 substrateNon-inhibitor0.726
CYP450 2C9 inhibitorNon-inhibitor0.9346
CYP450 2D6 inhibitorNon-inhibitor0.9702
CYP450 2C19 inhibitorNon-inhibitor0.9296
CYP450 3A4 inhibitorNon-inhibitor0.9772
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9163
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.7654
BiodegradationReady biodegradable0.9074
Rat acute toxicity1.3676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.9586
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (2.96 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-001j-9000000000-a705823ce4aeba7f89e1
Mass Spectrum (Electron Ionization)MSsplash10-003s-9000000000-dabf5a61c5a7da9fbe13
MS/MS Spectrum - EI-B (HITACHI RMU-7M) , PositiveLC-MS/MSsplash10-001j-9000000000-a705823ce4aeba7f89e1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-d75d9996bc68c673f090
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-893c2599624722912f25
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-8af4124822065023744f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-22231ed69c5f28bfed79
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-d2881505c47bbef13f18
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-2ed988bb761ac20ba44a
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as primary alcohols. These are compounds comprising the primary alcohol functional group, with the general structure RCOH (R=alkyl, aryl).
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Alcohols and polyols
Direct Parent
Primary alcohols
Alternative Parents
Hydrocarbon derivatives
Substituents
Hydrocarbon derivative / Primary alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
primary alcohol, alkyl alcohol, ethanols (CHEBI:16236) / a primary alcohol, a short-chain alcohol (ETOH)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Earl DE, Tietz EI: Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors. J Pharmacol Exp Ther. 2011 Apr;337(1):301-11. doi: 10.1124/jpet.110.178244. Epub 2011 Jan 24. [PubMed:21262851]
  6. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wang J, Lanfranco MF, Gibb SL, Ron D: Ethanol-mediated long-lasting adaptations of the NR2B-containing NMDA receptors in the dorsomedial striatum. Channels (Austin). 2011 May-Jun;5(3):205-9. Epub 2011 May 1. [PubMed:21289476]
  4. Ron D, Wang J: The NMDA Receptor and Alcohol Addiction . [PubMed:21204417]
  5. Williams K: Extracellular Modulation of NMDA Receptors . [PubMed:21204407]
  6. Xu M, Smothers CT, Woodward JJ: Effects of ethanol on phosphorylation site mutants of recombinant N-methyl-D-aspartate receptors. Alcohol. 2011 Jun;45(4):373-80. doi: 10.1016/j.alcohol.2010.08.015. Epub 2010 Dec 15. [PubMed:21163614]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transmitter-gated ion channel activity
Specific Function
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name
GLRA1
Uniprot ID
P23415
Uniprot Name
Glycine receptor subunit alpha-1
Molecular Weight
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Fuentealba J, Munoz B, Yevenes G, Moraga-Cid G, Perez C, Guzman L, Rigo JM, Aguayo LG: Potentiation and inhibition of glycine receptors by tutin. Neuropharmacology. 2011 Feb-Mar;60(2-3):453-9. doi: 10.1016/j.neuropharm.2010.10.023. Epub 2010 Oct 31. [PubMed:21044637]
  4. Baenziger JE, Corringer PJ: 3D structure and allosteric modulation of the transmembrane domain of pentameric ligand-gated ion channels. Neuropharmacology. 2011 Jan;60(1):116-25. doi: 10.1016/j.neuropharm.2010.08.007. Epub 2010 Aug 14. [PubMed:20713066]
  5. Ye Q, Koltchine VV, Mihic SJ, Mascia MP, Wick MJ, Finn SE, Harrison NL, Harris RA: Enhancement of glycine receptor function by ethanol is inversely correlated with molecular volume at position alpha267. J Biol Chem. 1998 Feb 6;273(6):3314-9. [PubMed:9452448]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transmitter-gated ion channel activity
Specific Function
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name
GLRA2
Uniprot ID
P23416
Uniprot Name
Glycine receptor subunit alpha-2
Molecular Weight
52001.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Ye Q, Koltchine VV, Mihic SJ, Mascia MP, Wick MJ, Finn SE, Harrison NL, Harris RA: Enhancement of glycine receptor function by ethanol is inversely correlated with molecular volume at position alpha267. J Biol Chem. 1998 Feb 6;273(6):3314-9. [PubMed:9452448]
  4. Baenziger JE, Corringer PJ: 3D structure and allosteric modulation of the transmembrane domain of pentameric ligand-gated ion channels. Neuropharmacology. 2011 Jan;60(1):116-25. doi: 10.1016/j.neuropharm.2010.08.007. Epub 2010 Aug 14. [PubMed:20713066]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
Gene Name
CHRNA10
Uniprot ID
Q9GZZ6
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-10
Molecular Weight
49704.295 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Pdz domain binding
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIA1
Uniprot ID
P42261
Uniprot Name
Glutamate receptor 1
Molecular Weight
101505.245 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA4
Uniprot ID
P48058
Uniprot Name
Glutamate receptor 4
Molecular Weight
100870.085 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Extracellular-glutamate-gated ion channel activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA3
Uniprot ID
P42263
Uniprot Name
Glutamate receptor 3
Molecular Weight
101155.975 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein activated inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ3
Uniprot ID
P48549
Uniprot Name
G protein-activated inward rectifier potassium channel 1
Molecular Weight
56602.84 Da
References
  1. Spanagel R: Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89(2):649-705. doi: 10.1152/physrev.00013.2008. [PubMed:19342616]
  2. Bodhinathan K, Slesinger PA: Molecular mechanism underlying ethanol activation of G-protein-gated inwardly rectifying potassium channels. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18309-14. doi: 10.1073/pnas.1311406110. Epub 2013 Oct 21. [PubMed:24145411]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inward rectifier potassium channel activity
Specific Function
This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are...
Gene Name
KCNJ6
Uniprot ID
P48051
Uniprot Name
G protein-activated inward rectifier potassium channel 2
Molecular Weight
48450.96 Da
References
  1. Spanagel R: Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89(2):649-705. doi: 10.1152/physrev.00013.2008. [PubMed:19342616]
  2. Bodhinathan K, Slesinger PA: Molecular mechanism underlying ethanol activation of G-protein-gated inwardly rectifying potassium channels. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18309-14. doi: 10.1073/pnas.1311406110. Epub 2013 Oct 21. [PubMed:24145411]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Primary amine oxidase activity
Specific Function
Important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and si...
Gene Name
VCAM1
Uniprot ID
P19320
Uniprot Name
Vascular cell adhesion protein 1
Molecular Weight
81275.43 Da
References
  1. Arevalo E, Shanmugasundararaj S, Wilkemeyer MF, Dou X, Chen S, Charness ME, Miller KW: An alcohol binding site on the neural cell adhesion molecule L1. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):371-5. doi: 10.1073/pnas.0707815105. Epub 2007 Dec 28. [PubMed:18165316]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR...
Gene Name
SLC29A1
Uniprot ID
Q99808
Uniprot Name
Equilibrative nucleoside transporter 1
Molecular Weight
50218.805 Da
References
  1. Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, Wyatt TA: Ethanol blocks adenosine uptake via inhibiting the nucleoside transport system in bronchial epithelial cells. Alcohol Clin Exp Res. 2009 May;33(5):791-8. doi: 10.1111/j.1530-0277.2009.00897.x. Epub 2009 Mar 6. [PubMed:19298329]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein activated inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ5
Uniprot ID
P48544
Uniprot Name
G protein-activated inward rectifier potassium channel 4
Molecular Weight
47667.3 Da
References
  1. Spanagel R: Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89(2):649-705. doi: 10.1152/physrev.00013.2008. [PubMed:19342616]
  2. Bodhinathan K, Slesinger PA: Molecular mechanism underlying ethanol activation of G-protein-gated inwardly rectifying potassium channels. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18309-14. doi: 10.1073/pnas.1311406110. Epub 2013 Oct 21. [PubMed:24145411]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Calcium channel activity
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasm...
Gene Name
CHRNA9
Uniprot ID
Q9UGM1
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-9
Molecular Weight
54806.63 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB4
Uniprot ID
P30926
Uniprot Name
Neuronal acetylcholine receptor subunit beta-4
Molecular Weight
56378.985 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA5
Uniprot ID
P30532
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-5
Molecular Weight
53053.965 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Acetylcholine-activated cation-selective channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA6
Uniprot ID
Q15825
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-6
Molecular Weight
56897.745 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB3
Uniprot ID
Q05901
Uniprot Name
Neuronal acetylcholine receptor subunit beta-3
Molecular Weight
52728.215 Da
References
  1. Hendrickson LM, Guildford MJ, Tapper AR: Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry. 2013 Apr 30;4:29. doi: 10.3389/fpsyt.2013.00029. eCollection 2013. [PubMed:23641218]
  2. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transmembrane signaling receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRQ
Uniprot ID
Q9UN88
Uniprot Name
Gamma-aminobutyric acid receptor subunit theta
Molecular Weight
72020.875 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Santhakumar V, Wallner M, Otis TS: Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol. 2007 May;41(3):211-21. [PubMed:17591544]
  2. Davies M: The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003 Jul;28(4):263-74. [PubMed:12921221]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, ...
Gene Name
SLC29A2
Uniprot ID
Q14542
Uniprot Name
Equilibrative nucleoside transporter 2
Molecular Weight
50112.335 Da
References
  1. Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, Wyatt TA: Ethanol blocks adenosine uptake via inhibiting the nucleoside transport system in bronchial epithelial cells. Alcohol Clin Exp Res. 2009 May;33(5):791-8. doi: 10.1111/j.1530-0277.2009.00897.x. Epub 2009 Mar 6. [PubMed:19298329]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin-activated cation-selective channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3E
Uniprot ID
A5X5Y0
Uniprot Name
5-hydroxytryptamine receptor 3E
Molecular Weight
51437.415 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin-activated cation-selective channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3B
Uniprot ID
O95264
Uniprot Name
5-hydroxytryptamine receptor 3B
Molecular Weight
50291.3 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin-activated cation-selective channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3D
Uniprot ID
Q70Z44
Uniprot Name
5-hydroxytryptamine receptor 3D
Molecular Weight
50190.625 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin-activated cation-selective channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3C
Uniprot ID
Q8WXA8
Uniprot Name
5-hydroxytryptamine receptor 3C
Molecular Weight
50219.07 Da
References
  1. Dopico AM, Lovinger DM: Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol Rev. 2009 Mar;61(1):98-114. doi: 10.1124/pr.108.000430. Epub 2009 Mar 6. [PubMed:19270242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by s...
Gene Name
CACNG2
Uniprot ID
Q9Y698
Uniprot Name
Voltage-dependent calcium channel gamma-2 subunit
Molecular Weight
35965.44 Da
References
  1. Hendricson AW, Thomas MP, Lippmann MJ, Morrisett RA: Suppression of L-type voltage-gated calcium channel-dependent synaptic plasticity by ethanol: analysis of miniature synaptic currents and dendritic calcium transients. J Pharmacol Exp Ther. 2003 Nov;307(2):550-8. Epub 2003 Sep 11. [PubMed:12970385]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein activated inward rectifier potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name
KCNJ9
Uniprot ID
Q92806
Uniprot Name
G protein-activated inward rectifier potassium channel 3
Molecular Weight
44019.45 Da
References
  1. Spanagel R: Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009 Apr;89(2):649-705. doi: 10.1152/physrev.00013.2008. [PubMed:19342616]
  2. Bodhinathan K, Slesinger PA: Molecular mechanism underlying ethanol activation of G-protein-gated inwardly rectifying potassium channels. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18309-14. doi: 10.1073/pnas.1311406110. Epub 2013 Oct 21. [PubMed:24145411]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors. During brain development, critical in multiple processes, including neuronal migration, axonal growth and fasciculation, and synaptogenesis. In the mature brain, plays a role in the dynamics of neuronal structure and function, including synaptic plasticity.
Specific Function
Protein domain specific binding
Gene Name
L1CAM
Uniprot ID
P32004
Uniprot Name
Neural cell adhesion molecule L1
Molecular Weight
140001.87 Da
References
  1. Arevalo E, Shanmugasundararaj S, Wilkemeyer MF, Dou X, Chen S, Charness ME, Miller KW: An alcohol binding site on the neural cell adhesion molecule L1. Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):371-5. doi: 10.1073/pnas.0707815105. Epub 2007 Dec 28. [PubMed:18165316]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH1A
Uniprot ID
P07327
Uniprot Name
Alcohol dehydrogenase 1A
Molecular Weight
39858.37 Da
References
  1. Hernandez-Tobias A, Julian-Sanchez A, Pina E, Riveros-Rosas H: Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. doi: 10.1016/j.cbi.2011.02.008. Epub 2011 Feb 15. [PubMed:21329681]
  2. Matsumoto M, Cyganek I, Sanghani PC, Cho WK, Liangpunsakul S, Crabb DW: Ethanol metabolism by HeLa cells transduced with human alcohol dehydrogenase isoenzymes: control of the pathway by acetaldehyde concentration. Alcohol Clin Exp Res. 2011 Jan;35(1):28-38. doi: 10.1111/j.1530-0277.2010.01319.x. [PubMed:21166830]
  3. Nishimura FT, Kimura Y, Abe S, Fukunaga T, Saijoh K: Effects of polymorphisms in untranslated regions of the class I alcohol dehydrogenase (ADH) genes on alcohol metabolism in Japanese subjects and transcriptional activity in HepG2 cells. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2009 Jun;44(3):139-55. [PubMed:19618839]
  4. Jelski W, Kozlowski M, Laudanski J, Niklinski J, Szmitkowski M: The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in esophageal cancer. Dig Dis Sci. 2009 Apr;54(4):725-30. doi: 10.1007/s10620-008-0422-8. Epub 2008 Aug 9. [PubMed:18688716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH1B
Uniprot ID
P00325
Uniprot Name
Alcohol dehydrogenase 1B
Molecular Weight
39854.21 Da
References
  1. Hernandez-Tobias A, Julian-Sanchez A, Pina E, Riveros-Rosas H: Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. doi: 10.1016/j.cbi.2011.02.008. Epub 2011 Feb 15. [PubMed:21329681]
  2. Matsumoto M, Cyganek I, Sanghani PC, Cho WK, Liangpunsakul S, Crabb DW: Ethanol metabolism by HeLa cells transduced with human alcohol dehydrogenase isoenzymes: control of the pathway by acetaldehyde concentration. Alcohol Clin Exp Res. 2011 Jan;35(1):28-38. doi: 10.1111/j.1530-0277.2010.01319.x. [PubMed:21166830]
  3. Nishimura FT, Kimura Y, Abe S, Fukunaga T, Saijoh K: Effects of polymorphisms in untranslated regions of the class I alcohol dehydrogenase (ADH) genes on alcohol metabolism in Japanese subjects and transcriptional activity in HepG2 cells. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2009 Jun;44(3):139-55. [PubMed:19618839]
  4. Jelski W, Kozlowski M, Laudanski J, Niklinski J, Szmitkowski M: The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in esophageal cancer. Dig Dis Sci. 2009 Apr;54(4):725-30. doi: 10.1007/s10620-008-0422-8. Epub 2008 Aug 9. [PubMed:18688716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH1C
Uniprot ID
P00326
Uniprot Name
Alcohol dehydrogenase 1C
Molecular Weight
39867.27 Da
References
  1. Hernandez-Tobias A, Julian-Sanchez A, Pina E, Riveros-Rosas H: Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. doi: 10.1016/j.cbi.2011.02.008. Epub 2011 Feb 15. [PubMed:21329681]
  2. Matsumoto M, Cyganek I, Sanghani PC, Cho WK, Liangpunsakul S, Crabb DW: Ethanol metabolism by HeLa cells transduced with human alcohol dehydrogenase isoenzymes: control of the pathway by acetaldehyde concentration. Alcohol Clin Exp Res. 2011 Jan;35(1):28-38. doi: 10.1111/j.1530-0277.2010.01319.x. [PubMed:21166830]
  3. Nishimura FT, Kimura Y, Abe S, Fukunaga T, Saijoh K: Effects of polymorphisms in untranslated regions of the class I alcohol dehydrogenase (ADH) genes on alcohol metabolism in Japanese subjects and transcriptional activity in HepG2 cells. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2009 Jun;44(3):139-55. [PubMed:19618839]
  4. Jelski W, Kozlowski M, Laudanski J, Niklinski J, Szmitkowski M: The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in esophageal cancer. Dig Dis Sci. 2009 Apr;54(4):725-30. doi: 10.1007/s10620-008-0422-8. Epub 2008 Aug 9. [PubMed:18688716]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Class-III ADH is remarkably ineffective in oxidizing ethanol, but it readily catalyzes the oxidation of long-chain primary alcohols and the oxidation of S-(hydroxymethyl) glutathione.
Gene Name
ADH5
Uniprot ID
P11766
Uniprot Name
Alcohol dehydrogenase class-3
Molecular Weight
39723.945 Da
References
  1. Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ: Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. [PubMed:16792560]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH4
Uniprot ID
P08319
Uniprot Name
Alcohol dehydrogenase 4
Molecular Weight
40221.335 Da
References
  1. Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ: Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. [PubMed:16792560]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Could function in retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation. Medium-chain (octanol) and aromatic (m-nitrobenzaldehyde) compounds are the...
Gene Name
ADH7
Uniprot ID
P40394
Uniprot Name
Alcohol dehydrogenase class 4 mu/sigma chain
Molecular Weight
41480.985 Da
References
  1. Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ: Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. [PubMed:16792560]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
ADH6
Uniprot ID
P28332
Uniprot Name
Alcohol dehydrogenase 6
Molecular Weight
39088.335 Da
References
  1. Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ: Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. [PubMed:16792560]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
L-glucuronate reductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyd...
Gene Name
AKR1A1
Uniprot ID
P14550
Uniprot Name
Alcohol dehydrogenase [NADP(+)]
Molecular Weight
36572.71 Da
References
  1. Lee SL, Chau GY, Yao CT, Wu CW, Yin SJ: Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. [PubMed:16792560]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18